Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2025 Revenue and EBITDA guidance Remaining performance obligations increased by 25% YOY to $62 million Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advance ...

Core Insights - BrainsWay is launching two new Continuing Medical Education (CME) courses to enhance clinician knowledge and confidence in Transcranial Magnetic Stimulation (TMS) [1][2] - The courses are designed to clarify the differences between BrainsWay's Deep TMS™ technology and first-generation TMS, while providing practical guidance for clinical integration [1][3] Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, focusing on its proprietary Deep TMS™ platform technology [5] - The company has received FDA clearance for three indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction, supported by pivotal clinical studies [5] - BrainsWay aims to increase global awareness and access to Deep TMS, with ongoing clinical trials for various psychiatric, neurological, and addiction disorders [5] Educational Initiatives - The CME courses are supported by independent educational grants from BrainsWay and offer up to 0.5 AMA PRA Category 1 Credits™ [2] - The courses are accessible online to a wide range of healthcare professionals, including psychiatrists and nurse practitioners [2] - The first course focuses on evidence-based data supporting TMS and its role in mental health treatment, while the second course emphasizes practical strategies for patient identification and treatment integration [6]